We are pleased to invite you to read the top 10 cited papers in 2021 in Cancers (ISSN: 2072-6694) in the Section “Cancer Drug Development”. The paper list is as follows:

1. “Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma”
by Hamid Maadi, Mohammad Hasan Soheilifar, Won-Shik Choi, Abdolvahab Moshtaghian and Zhixiang Wang
Cancers 2021, 13(14), 3540; https://doi.org/10.3390/cancers13143540
Available online: https://www.mdpi.com/2072-6694/13/14/3540

2. “Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer”
by Ryan W. Holloway and Paola A. Marignani
Cancers 2021, 13(12), 2922; https://doi.org/10.3390/cancers13122922
Available online: https://www.mdpi.com/2072-6694/13/12/2922

3. “CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development”
by Kenji Hashimoto
Cancers 2021, 13(10), 2288; https://doi.org/10.3390/cancers13102288
Available online: https://www.mdpi.com/2072-6694/13/10/2288

4. “HSP90α Mediates Sorafenib Resistance in Human Hepatocellular Carcinoma by Necroptosis Inhibition under Hypoxia”
by Yan Liao, Yue Yang, Di Pan, Youxiang Ding, Heng Zhang, Yuting Ye, Jia Li and Li Zhao
Cancers 2021, 13(2), 243; https://doi.org/10.3390/cancers13020243
Available online: https://www.mdpi.com/2072-6694/13/2/243

5. “Sulforaphane Inhibits the Expression of Long Noncoding RNA H19 and Its Target APOBEC3G and Thereby Pancreatic Cancer Progression”
by Yiqiao Luo, Bin Yan, Li Liu, Libo Yin, Huihui Ji, Xuefeng An, Jury Gladkich, Zhimin Qi, Carolina De La Torre and Ingrid Herr
Cancers 2021, 13(4), 827; https://doi.org/10.3390/cancers13040827
Available online: https://www.mdpi.com/2072-6694/13/4/827

6. “Biological Significance and Targeting of the FGFR Axis in Cancer”
by Athina-Myrto Chioni and Richard P. Grose
Cancers 2021, 13(22), 5681; https://doi.org/10.3390/cancers13225681
Available online: https://www.mdpi.com/2072-6694/13/22/5681

7. “Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities”
by Chenyin Wang, Alexandra Hamacher, Patrick Petzsch, Karl Köhrer, Günter Niegisch, Michèle J. Hoffmann, Wolfgang A. Schulz and Matthias U. Kassack
Cancers 2021, 13(8), 1781; https://doi.org/10.3390/cancers13081781
Available online: https://www.mdpi.com/2072-6694/13/8/1781

8. “Autophagy Inhibition in BRAF-Driven Cancers”
by Mona Foth and Martin McMahon
Cancers 2021, 13(14), 3498; https://doi.org/10.3390/cancers13143498
Available online: https://www.mdpi.com/2072-6694/13/14/3498

9. “IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma”
by Hima Patel, Rosalin Mishra, Nour Yacoub, Samar Alanazi, Mary Kate Kilroy and Joan T. Garrett
Cancers 2021, 13(22), 5863; https://doi.org/10.3390/cancers13225863
Available online: https://www.mdpi.com/2072-6694/13/22/5863

10. “FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers”
by Katia A. Mesquita, Reem Ali, Rachel Doherty, Michael S. Toss, Islam Miligy, Adel Alblihy, Dorjbal Dorjsuren, Anton Simeonov, Ajit Jadhav, David M. Wilson III et al.
Cancers 2021, 13(8), 1866; https://doi.org/10.3390/cancers13081866
Available online: https://www.mdpi.com/2072-6694/13/8/1866